secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001558370-24-003940
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports FY2023 net loss of $22.3M; cash runway into Q1 2025
-----------------------------------------------------------------------------

- Net loss for FY2023 was $22.3M ($1.71 per share), vs $17.6M ($1.48) in FY2022.
- R&D expenses rose to $11.5M from $8.4M due to Phase 1 trial of GT-02287 for GBA1 Parkinson's disease.
- Cash and marketable securities $16.8M as of Dec 31, 2023; expected to fund operations into Q1 2025.
- Initiated MAD part of Phase 1 trial of GT-02287; data presented at AD/PD 2024 and WORLD Symposium.
- Raised $10.1M gross proceeds from public offering and private placement in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/0001558370-24-003940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024003940/ganx-20240326x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-003940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer